NTLA · Intellia Therapeutics, Inc.
$12.90
+0.46 (+3.70%)
At close · Aug 21
Market Cap
$1.86B
Shares
140.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.44
Open$12.95
Day$12.29–13.04
52W close$8.04–27.98
Avg vol 30d3.9M
Short int44.0M · 31.4% float · 12.0d
Short vol47%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−6%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−10%
trailing
YTD return
+38%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$135.6K over 90 days · 100% sells
Short interest
Falling
31.41% of float · ▼ -3.9% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
331 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-395.9M
Balance sheet
$155.5M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2025
Year-over-year decline in GAAP operating expenses
· full year
GAAP
at least 10%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$135.6K over 90 days · 100% sells
Short interest
Falling
31.41% of float · ▼ -3.9% MoM · 12.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
331 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $12 · 22%
Range high $28
vs 200-day avg +0%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $628.4M | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTLA
this stock
Intellia Therapeutics, Inc.
|
$1.86B | +38.4% | +16.9% | — | 31.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTLA | +5.2% | +12.1% | -9.7% | +16.5% | +38.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +7.1% | +8.8% | -20.9% | +14.4% | +26.6% |
Key facts
CIK
1652130
CUSIP
45826J105
13F (30d)
325 filings
299 filers
Visit website
Investor relations